SCHEMBL6320941

SCHEMBL6320941

CCc1ccc(-c2noc(N)c2C(=O)NCCC(c2ccccc2)c2ccccc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.47
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.40
HPGD P15428 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6619619 0.92 EPHX2 (0.39) EPHX2NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL6323623 0.90 EPHX2 (0.49) EPHX2NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL6318990 0.88 CA1 (0.41) EPHX2NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL6317382 0.87 CA1 (0.52) EPHX2NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL6324432 0.87 EPHX2 (0.48) EPHX2NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL6317389 0.86 NPC1 (0.53) MAPTALDH1A1SMN1; SMN2MAPK1HTT
SCHEMBL6322146 0.85 HPGDS (0.44) NPSR1ALDH1A1SMN1; SMN2CYP2C9CYP2C19
SCHEMBL6318063 0.84 L3MBTL1 (0.54) NPSR1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL6318494 0.84 L3MBTL1 (0.47) NPSR1ALDH1A1MAPK1KDM4EHPGD
SCHEMBL6317805 0.83 GAA (0.48) NPSR1MAPTALDH1A1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 EPHX2 4156/4885NPSR1 4399/4885MAPT 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.